C
4892
vs
N
Nikkei 225
Over the past 12 months, Cyfuse Biomedical KK has underperformed Nikkei 225, delivering a return of -37% compared to the Nikkei 225's +71% growth.
Stocks Performance
4892 vs Nikkei 225
Performance Gap
4892 vs Nikkei 225
Performance By Year
4892 vs Nikkei 225
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cyfuse Biomedical KK
Glance View
Cyfuse Biomedical KK develops and manufactures cell regenerative systems. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2022-12-01. The firm is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The firm is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The firm is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.
